Knight Therapeutics (TSX:GUD) Cash-to-Debt : 2.46 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Knight Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.46.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Knight Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Knight Therapeutics's Cash-to-Debt or its related term are showing as below:

TSX:GUD' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.46 Med: 5003.66 Max: No Debt
Current: 2.46

During the past 11 years, Knight Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.46. And the median was 5003.66.

TSX:GUD's Cash-to-Debt is ranked better than
63.87% of 1049 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs TSX:GUD: 2.46

Knight Therapeutics Cash-to-Debt Historical Data

The historical data trend for Knight Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Knight Therapeutics Cash-to-Debt Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

6.93

7.32

3.98

2.46

Knight Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.46	2.22	2.06	2.23	2.46

Competitive Comparison of Knight Therapeutics's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Cash-to-Debt falls into.

Knight Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Knight Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	170.171	/	(19.578	+	49.513)
	=	2.46

Knight Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	170.171	/	(19.578	+	49.513)
	=	2.46

Knight Therapeutics (TSX:GUD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Knight Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics (TSX:GUD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Executives

Sime Armoyan

10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines